论文部分内容阅读
目的:观察冠心病患者血中凝集素样氧化低密度脂蛋白受体-1(LOX-1)、基质金属蛋白酶-9(MMP-9)水平变化及其相关性。方法:采用酶联免疫吸附法测定20例急性冠状动脉综合征患者(ACS组)、20例稳定型心绞痛患者(SA组)、20例非冠心病患者(对照组)血清LOX-1、MMP-9水平的变化。结果:①ACS组患者血清LOX-1、MMP-9水平高于SA组(均P<0.05)及对照组(均P<0.01);SA组患者血清LOX-1、MMP-9水平高于对照组(均P<0.05);ACS患者治疗2周后LOX-1、MMP-9较治疗前显著下降(P<0.01);②LOX-1、MMP-9的ROC曲线下面积分分别为0.786、0.716,且差异有统计学意义。结论:ACS患者血清LOX-1、MMP-9水平显著升高,二者可作为斑块不稳定的判断指标。
Objective: To investigate the changes of blood levels of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) and matrix metalloproteinase-9 (MMP-9) in patients with coronary heart disease and their correlation. Methods: Serum levels of LOX-1 and MMP-2 in 20 patients with acute coronary syndrome (ACS group), 20 patients with stable angina pectoris (SA group) and 20 patients with non-coronary heart disease (control group) were measured by enzyme-linked immunosorbent assay 9 levels of change. Results: ① The serum levels of LOX-1 and MMP-9 in ACS group were significantly higher than those in SA group (all P <0.05) and control group (all P <0.01). The levels of serum LOX-1 and MMP-9 in SA group were higher than those in control group (P <0.05). The LOX-1 and MMP-9 levels were significantly decreased in ACS patients after 2 weeks of treatment (P <0.01); ② The ROC curves of LOX-1 and MMP-9 were 0.786 and 0.716 respectively The difference was statistically significant. Conclusion: Serum levels of LOX-1 and MMP-9 in patients with ACS are significantly higher than those in patients with ACS, and both can be used as indicators of plaque instability.